Breaking News Instant updates and real-time market news.

FNSR

Acquired by IIVI

$19.70 /

-0.035 (-0.18%)

, CIEN

Ciena

$31.63 /

+0.33 (+1.05%)

07:45
09/13/18
09/13
07:45
09/13/18
07:45

Morgan Stanley goes to Equal Weight on optical, downgrades Finisar and Ciena

As previously reported, Morgan Stanley analyst Meta Marshall downgraded Finisar (FNSR) and Ciena (CIEN), both to Equal Weight from Overweight, as she adjusted her Optical Scorecard following the earnings reports from companies in the sector. The two stocks have closed the short-term valuation gaps that she previously believed existed with their respective moves up of about 35% since April for Finisar and 25% since June for Ciena, Marshall tells investors. The analyst added that she is being cautious ahead of Ciena's FY19 guidance, though she raised her price target on the stock to $32 from $30. Marshall, who keeps a $20 price target on Finisar shares, said she thinks its catalysts don't come until calendar 2019. The analyst also noted that with these two downgrades, she is now Equal Weight on the space as a whole, as she also has Equal Weight ratings on Lumentum (LITE), II-VI (IIVI) and Acacia Communications (ACIA).

FNSR

Acquired by IIVI

$19.70 /

-0.035 (-0.18%)

CIEN

Ciena

$31.63 /

+0.33 (+1.05%)

LITE

Lumentum

$60.70 /

-0.65 (-1.06%)

IIVI

II-VI

$46.90 /

-0.15 (-0.32%)

ACIA

Acacia Communications

$40.07 /

-0.1 (-0.25%)

  • 13

    Sep

  • 13

    Sep

  • 25

    Sep

  • 01

    Oct

  • 02

    Oct

FNSR Acquired by IIVI
$19.70 /

-0.035 (-0.18%)

09/13/18 Morgan Stanley
Finisar downgraded to Equal Weight from Overweight at Morgan Stanley
09/07/18 Loop Capital
Finisar price target lowered to $20 from $22 at Loop Capital
09/07/18 Piper Sandler
Piper continues to like setup for Finisar after 'impressive' results
08/29/18 MKM Partners
Finisar may be faced with 'period of consolidation', says MKM Partners
CIEN Ciena
$31.63 /

+0.33 (+1.05%)

09/13/18 Morgan Stanley
Ciena downgraded to Equal Weight from Overweight at Morgan Stanley
09/05/18 Argus
Ciena price target raised to $38 from $33 at Argus
08/31/18 Jefferies
Jefferies says don't sell Ciena, ups price target to $38
08/31/18 MKM Partners
Ciena price target raised to $36 from $32 at MKM Partners
LITE Lumentum
$60.70 /

-0.65 (-1.06%)

09/05/18 Needham
Lumentum price target raised to $90 from $80 at Needham
09/04/18 JPMorgan
JPMorgan sees upside to Lumentum estimates from world facing applications
08/13/18 Piper Sandler
Oclaro combination with Lumentum creates 'powerhouse,' says Piper Jaffray
08/09/18 MKM Partners
Lumentum price target lowered to $78 from $84 at MKM PartnersII-VI
IIVI II-VI
$46.90 /

-0.15 (-0.32%)

09/04/18 B. Riley
II-VI downgraded to Neutral from Buy at B. Riley FBR
08/28/18
On The Fly: Top five analyst initiations
08/28/18 Deutsche Bank
Deutsche says II-VI growth not reflected in valuation, starts with Buy rating
08/27/18 Deutsche Bank
II-VI initiated with a Buy at Deutsche Bank
ACIA Acacia Communications
$40.07 /

-0.1 (-0.25%)

08/24/18
Acacia Communications downgraded to Underperform at BofA/Merrill
08/24/18 BofA
Acacia Communications downgraded to Underperform from Neutral at BofA/Merrill
08/23/18 Piper Sandler
Finisar upgraded to Overweight from Neutral at Piper Jaffray
08/23/18 Piper Sandler
Acacia Communications upgraded to Overweight from Neutral at Piper Jaffray

TODAY'S FREE FLY STORIES

Hot Stocks
Arctic Vision, Eyenovia to partner on MydCombi commercialization in China, Korea » 20:18
09/16/21
09/16
20:18
09/16/21
20:18
EYEN

Eyenovia

$4.45 /

+ (+0.00%)

Arctic Vision announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EYEN Eyenovia
$4.45 /

+ (+0.00%)

EYEN Eyenovia
$4.45 /

+ (+0.00%)

04/01/21 H.C. Wainwright
Eyenovia price target raised to $8 from $6 at H.C. Wainwright
03/01/21 Northland
Eyenovia initiated with an Outperform at Northland
12/30/20 H.C. Wainwright
H.C. Wainwright reiterates $6 target on Eyenovia after new drug submission
10/23/20 H.C. Wainwright
Eyenovia price target lowered to $6 from $7 at H.C. Wainwright
EYEN Eyenovia
$4.45 /

+ (+0.00%)

Initiation
Twilio assumed with a Buy at Summit Insights » 20:03
09/16/21
09/16
20:03
09/16/21
20:03
TWLO

Twilio

$345.87 /

+4.025 (+1.18%)

Summit Insights analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TWLO Twilio
$345.87 /

+4.025 (+1.18%)

TWLO Twilio
$345.87 /

+4.025 (+1.18%)

07/30/21 Baird
Twilio price target raised to $450 from $430 at Baird
07/30/21 Mizuho
Twilio price target raised to $430 from $400 at Mizuho
07/30/21 RBC Capital
Twilio price target raised to $450 from $415 at RBC Capital
07/30/21 Jefferies
Twilio price target raised to $450 from $415 at Jefferies
TWLO Twilio
$345.87 /

+4.025 (+1.18%)

  • 19
    Feb
TWLO Twilio
$345.87 /

+4.025 (+1.18%)

TWLO Twilio
$345.87 /

+4.025 (+1.18%)

TWLO Twilio
$345.87 /

+4.025 (+1.18%)

Downgrade
Ferrari cut to Neutral at Exane BNP Paribas on slow cyclical recovery » 20:01
09/16/21
09/16
20:01
09/16/21
20:01
RACE

Ferrari

$218.94 /

-2.76 (-1.24%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RACE Ferrari
$218.94 /

-2.76 (-1.24%)

RACE Ferrari
$218.94 /

-2.76 (-1.24%)

12:14 Today Exane BNP Paribas
Ferrari downgraded to Neutral from Outperform at Exane BNP Paribas
09/15/21 BofA
BofA calls Lucid the 'Tesla/Ferrari of new EV automakers,' starts at Buy
09/09/21 Oddo BHF
Ferrari initiated with an Outperform at Oddo BHF
07/16/21 BofA
Ferrari price target lowered to $281 from $287 at BofA
RACE Ferrari
$218.94 /

-2.76 (-1.24%)

RACE Ferrari
$218.94 /

-2.76 (-1.24%)

RACE Ferrari
$218.94 /

-2.76 (-1.24%)

Downgrade
Autoliv downgraded to Underperform from Neutral at Exane BNP Paribas » 19:57
09/16/21
09/16
19:57
09/16/21
19:57
ALV

Autoliv

$84.36 /

-3.8 (-4.31%)

Exane BNP Paribas analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ALV Autoliv
$84.36 /

-3.8 (-4.31%)

ALV Autoliv
$84.36 /

-3.8 (-4.31%)

12:06 Today Exane BNP Paribas
Autoliv downgraded to Underperform from Neutral at Exane BNP Paribas
07/19/21 Deutsche Bank
Autoliv price target lowered to $96 from $101 at Deutsche Bank
07/19/21 Mizuho
Autoliv price target lowered to $112 from $115 at Mizuho
07/19/21 RBC Capital
Autoliv price target lowered to $104 from $117 at RBC Capital
ALV Autoliv
$84.36 /

-3.8 (-4.31%)

ALV Autoliv
$84.36 /

-3.8 (-4.31%)

Upgrade
Lagardere upgraded to Neutral from Underperform at Exane BNP Paribas » 19:51
09/16/21
09/16
19:51
09/16/21
19:51
LGDDF

Lagardere

$26.49 /

+ (+0.00%)

, VIVHY

Vivendi

$37.47 /

+0.17 (+0.46%)

Exane BNP Paribas analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VIVHY Vivendi
$37.47 /

+0.17 (+0.46%)

LGDDF Lagardere
$26.49 /

+ (+0.00%)

07/28/21 Barclays
Lagardere price target raised to EUR 25.50 from EUR 24.50 at Barclays
07/27/21 Societe Generale
Lagardere upgraded to Buy from Hold at Societe Generale
05/06/21 Oddo BHF
Lagardere upgraded to Neutral from Underperform at Oddo BHF
03/01/21 Barclays
Lagardere price target raised to EUR 24.50 from EUR 20 at Barclays
VIVHY Vivendi
$37.47 /

+0.17 (+0.46%)

08/26/21 UBS
Vivendi price target raised to EUR 41 from EUR 38 at UBS
08/26/21 JPMorgan
Vivendi price target raised to EUR 45 from EUR 44 at JPMorgan
08/26/21 Barclays
Vivendi upgraded to Overweight from Equal Weight at Barclays
07/29/21 Credit Suisse
Vivendi price target raised to EUR 33.60 from EUR 32.20 at Credit Suisse
VIVHY Vivendi
$37.47 /

+0.17 (+0.46%)

VIVHY Vivendi
$37.47 /

+0.17 (+0.46%)

Hot Stocks
Novavax to participate in Oxford Com-COV3 study » 19:04
09/16/21
09/16
19:04
09/16/21
19:04
NVAX

Novavax

$237.14 /

+5.03 (+2.17%)

Novavax announced its…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NVAX Novavax
$237.14 /

+5.03 (+2.17%)

NVAX Novavax
$237.14 /

+5.03 (+2.17%)

09/08/21 Cantor Fitzgerald
Novavax combo vaccine could have 'differentiating' value, says Cantor Fitzgerald
08/30/21 B. Riley
Novavax is leader in making Covid-flu combination candidate, says B. Riley
08/04/21 Cantor Fitzgerald
Novavax EU deal suggests bottlenecks have been resolved, says Cantor Fitzgerald
06/15/21 Cantor Fitzgerald
Novavax price target raised to $272 from $217 at Cantor Fitzgerald
NVAX Novavax
$237.14 /

+5.03 (+2.17%)

NVAX Novavax
$237.14 /

+5.03 (+2.17%)

NVAX Novavax
$237.14 /

+5.03 (+2.17%)

NVAX Novavax
$237.14 /

+5.03 (+2.17%)

On The Fly
Fly Intel: After-Hours Movers » 19:03
09/16/21
09/16
19:03
09/16/21
19:03
ABCL

AbCellera

$19.80 /

+1.03 (+5.49%)

, FANG

Diamondback Energy

$79.98 /

-1.63 (-2.00%)

, AGEN

Agenus

$5.57 /

+0.19 (+3.53%)

, CVGW

Calavo Growers

$36.64 /

+1.72 (+4.93%)

, OPAD

Offerpad Solutions

$20.17 /

+7.395 (+57.89%)

, IRNT

IronNet

$41.31 /

+9.255 (+28.87%)

, USNA

Usana

$87.51 /

+0.085 (+0.10%)

, X

U.S. Steel

$25.40 /

-0.27 (-1.05%)

Check out this evening's…

ShowHide Related Items >><<
ABCL AbCellera
$19.80 /

+1.03 (+5.49%)

FANG Diamondback Energy
$79.98 /

-1.63 (-2.00%)

AGEN Agenus
$5.57 /

+0.19 (+3.53%)

CVGW Calavo Growers
$36.64 /

+1.72 (+4.93%)

OPAD Offerpad Solutions
$20.17 /

+7.395 (+57.89%)

IRNT IronNet
$41.31 /

+9.255 (+28.87%)

USNA Usana
$87.51 /

+0.085 (+0.10%)

X U.S. Steel
$25.40 /

-0.27 (-1.05%)

ABCL AbCellera
$19.80 /

+1.03 (+5.49%)

06/11/21 BMO Capital
AbCellera coverage transferred at BMO Capital
03/30/21 SVB Leerink
AbCellera price target lowered to $45 from $52 at SVB Leerink
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
02/08/21 SVB Leerink
AbCellera price target raised to $52 from $45 at SVB Leerink
FANG Diamondback Energy
$79.98 /

-1.63 (-2.00%)

09/15/21 Truist
Diamondback Energy price target raised to $130 from $122 at Truist
07/22/21 Piper Sandler
Diamondback Energy price target raised to $112 from $102 at Piper Sandler
07/15/21 Mizuho
Diamondback Energy price target raised to $131 from $120 at Mizuho
07/07/21 Wells Fargo
Diamondback Energy price target raised to $101 from $90 at Wells Fargo
AGEN Agenus
$5.57 /

+0.19 (+3.53%)

09/07/21 B. Riley
Agenus price target raised to $12 from $11 at B. Riley
06/28/21 B. Riley
Agenus price target raised to $11 from $8 at B. Riley
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
09/22/20 B. Riley FBR
B. Riley FBR calls Agenus 'hidden gem' amidst ESMO data releases
CVGW Calavo Growers
$36.64 /

+1.72 (+4.93%)

09/09/21 Lake Street
Calavo Growers price target lowered to $60 from $70 at Lake Street
08/05/21 Lake Street
Calavo Growers price target lowered to $70 from $85 at Lake Street
06/04/21 Lake Street
Calavo Growers assumed with a Buy at Lake Street
03/11/21 Lake Street
Calavo Growers price target raised to $73 from $62 at Lake Street
OPAD Offerpad Solutions
$20.17 /

+7.395 (+57.89%)

IRNT IronNet
$41.31 /

+9.255 (+28.87%)

USNA Usana
$87.51 /

+0.085 (+0.10%)

02/10/21 Roth Capital
Usana price target raised to $126 from $107 at Roth Capital
12/17/20 Roth Capital
Usana initiated with a Buy at Roth Capital
X U.S. Steel
$25.40 /

-0.27 (-1.05%)

09/15/21 Deutsche Bank
U.S. Steel price target raised to $50 from $38 at Deutsche Bank
07/07/21 Credit Suisse
Steel demand booming in the U.S., says Credit Suisse
07/01/21 Deutsche Bank
U.S. Steel price target raised to $38 from $30 at Deutsche Bank
06/16/21
Fly Intel: Top five analyst downgrades
ABCL AbCellera
$19.80 /

+1.03 (+5.49%)

FANG Diamondback Energy
$79.98 /

-1.63 (-2.00%)

AGEN Agenus
$5.57 /

+0.19 (+3.53%)

CVGW Calavo Growers
$36.64 /

+1.72 (+4.93%)

USNA Usana
$87.51 /

+0.085 (+0.10%)

X U.S. Steel
$25.40 /

-0.27 (-1.05%)

  • 03
    Feb
  • 11
    Dec
X U.S. Steel
$25.40 /

-0.27 (-1.05%)

ABCL AbCellera
$19.80 /

+1.03 (+5.49%)

AGEN Agenus
$5.57 /

+0.19 (+3.53%)

CVGW Calavo Growers
$36.64 /

+1.72 (+4.93%)

IRNT IronNet
$41.31 /

+9.255 (+28.87%)

X U.S. Steel
$25.40 /

-0.27 (-1.05%)

ABCL AbCellera
$19.80 /

+1.03 (+5.49%)

FANG Diamondback Energy
$79.98 /

-1.63 (-2.00%)

AGEN Agenus
$5.57 /

+0.19 (+3.53%)

OPAD Offerpad Solutions
$20.17 /

+7.395 (+57.89%)

IRNT IronNet
$41.31 /

+9.255 (+28.87%)

X U.S. Steel
$25.40 /

-0.27 (-1.05%)

Hot Stocks
Agenus to present data on combination of Balstilimab and Zalifrelimab at ESMO » 18:33
09/16/21
09/16
18:33
09/16/21
18:33
AGEN

Agenus

$5.57 /

+0.19 (+3.53%)

Agenus presented final…

Agenus presented final results from the Bal/Zal combination study at the European Society for Medical Oncology Virtual Conference 2021 in an abstract titled Balstilimab in combination with zalifrelimab: final results from a Phase 2 study in patients with recurrent/metastatic cervical cancer... The Phase 2 trial was conducted in 155 patients with recurrent/metastatic cervical cancer which has limited effective treatment options and disproportionately affects younger women. In the 125 evaluable patients, the objective response rate in all patients was 26%, with 9% of patients achieving a complete response, and 17% of patients achieving a partial response. The median duration of response was not reached after a 19.4-month median follow-up. Notably, responses were also observed in the PD-L1 negative and adenocarcinoma populations, with 9% of both patient groups achieving an ORR. Based on these observations, we predict more than half of the patients to be alive beyond 12 months. The Bal/Zal combination continued to show no unexpected toxicities and no new safety signals were identified. Steven O'Day, MD, Chief Medical Officer of Agenus, stated: "With a median follow-up of almost 2 years, the Bal/Zal combination showed high response rates, durable clinical activity, and promising overall survival results. Furthermore, later this year we expect to present new data on our next-generation CTLA-4 inhibitor AGEN1181, which we expect to further define the positive role this combination strategy could have in addressing unmet needs for cancer patients."

ShowHide Related Items >><<
AGEN Agenus
$5.57 /

+0.19 (+3.53%)

AGEN Agenus
$5.57 /

+0.19 (+3.53%)

09/07/21 B. Riley
Agenus price target raised to $12 from $11 at B. Riley
06/28/21 B. Riley
Agenus price target raised to $11 from $8 at B. Riley
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
09/22/20 B. Riley
B. Riley FBR calls Agenus 'hidden gem' amidst ESMO data releases
AGEN Agenus
$5.57 /

+0.19 (+3.53%)

AGEN Agenus
$5.57 /

+0.19 (+3.53%)

AGEN Agenus
$5.57 /

+0.19 (+3.53%)

Hot Stocks
Sight Sciences files patent infringement lawsuit against Ivantis » 18:30
09/16/21
09/16
18:30
09/16/21
18:30
SGHT

Sight Sciences

$28.33 /

-0.47 (-1.63%)

Sight Sciences announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SGHT Sight Sciences
$28.33 /

-0.47 (-1.63%)

SGHT Sight Sciences
$28.33 /

-0.47 (-1.63%)

09/15/21 Piper Sandler
Piper says Glaukos patent settlement doesn't ease reimbursement challenges
08/09/21
Fly Intel: Top five analyst initiations
08/09/21 BofA
Sight Sciences initiated with a Buy at BofA
08/09/21 Citi
Sight Sciences initiated with a Buy at Citi
  • 15
    Jul
SGHT Sight Sciences
$28.33 /

-0.47 (-1.63%)

Hot Stocks
Coherus, Junshi to present PFS, OS results from JUPITER-06 » 18:29
09/16/21
09/16
18:29
09/16/21
18:29
CHRS

Coherus Biosciences

$16.04 /

+0.29 (+1.84%)

Coherus Biosciences and…

Coherus Biosciences and Shanghai Junshi Biosciences announced positive interim results from the pivotal study "JUPITER-06," a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab in combination with chemotherapy as a first-line therapy for patients with advanced or metastatic esophageal squamous cell carcinoma. The study met the co-primary endpoints with statistically significant and clinically meaningful improvements in progression free survival and overall survival for patients treated with the toripalimab and chemotherapy combination compared to chemotherapy alone. The results will be summarized by Dr. Feng Wang, Professor at Sun Yat-sen University Cancer Center, Guangzhou, in a mini-oral session during the ESMO Congress 2021 on Friday, September 17, 2021 at 12:05 pm Eastern Time. The abstract is now available on the ESMO website. "The findings of this interim analysis provide strong evidence that the addition of toripalimab to chemotherapy as a first-line treatment for advanced or metastatic ESCC patients has superior PFS and OS than chemotherapy alone," said Dr. Wang. "We look forward to updated analyses of overall survival of the JUPITER-06 study in the future and believe that these results will build a strong argument to support the use of toripalimab in combination with chemotherapy as a new standard first-line treatment in patients with advanced or metastatic ESCC." "A strong and consistent efficacy and safety profile is emerging for toripalimab across multiple tumor types as data read out from pivotal clinical trials in melanoma, nasopharyngeal carcinoma, urothelial cancer, lung cancer and now also esophageal squamous cell carcinoma," said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. "We believe toripalimab could be a potential new treatment choice where patients truly need better options. We will collaborate with Coherus to advance a BLA supplement for ESCC to make toripalimab available as quickly as possible for these patients in the U.S."

ShowHide Related Items >><<
CHRS Coherus Biosciences
$16.04 /

+0.29 (+1.84%)

CHRS Coherus Biosciences
$16.04 /

+0.29 (+1.84%)

07/23/21 H.C. Wainwright
Coherus Biosciences price target raised to $36 from $26 at H.C. Wainwright
05/17/21 Barclays
Coherus Biosciences price target lowered to $24 from $28 at Barclays
05/07/21 H.C. Wainwright
Coherus Biosciences price target lowered to $26 from $28 at H.C. Wainwright
02/25/21 Citi
Coherus Biosciences price target lowered to $27 from $30 at Citi
CHRS Coherus Biosciences
$16.04 /

+0.29 (+1.84%)

Hot Stocks
Dixie Group sells its AtlasMasland commercial business for $27.5M » 18:07
09/16/21
09/16
18:07
09/16/21
18:07
DXYN

Dixie Group

$5.39 /

+0.08 (+1.51%)

Dixie Group announced the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DXYN Dixie Group
$5.39 /

+0.08 (+1.51%)

DXYN Dixie Group
$5.39 /

+0.08 (+1.51%)

Hot Stocks
McAfee CFO sells 29,630 class A shares » 18:05
09/16/21
09/16
18:05
09/16/21
18:05
MCFE

McAfee

$21.78 /

+0.58 (+2.74%)

In a regulatory filing,…

In a regulatory filing, McAfee CFO Venkat Bhamidipati disclosed the sale of 29,630 class A common shares of the company on September 14 at a price of $21.7125 per share.

ShowHide Related Items >><<
MCFE McAfee
$21.78 /

+0.58 (+2.74%)

MCFE McAfee
$21.78 /

+0.58 (+2.74%)

09/13/21 Morgan Stanley
McAfee pullback a 'strong buying opportunity,' says Morgan Stanley
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 UBS
McAfee resumed to Neutral from Buy at UBS
06/17/21 Mizuho
McAfee price target raised to $30 from $28 at Mizuho
MCFE McAfee
$21.78 /

+0.58 (+2.74%)

  • 10
    Sep
  • 22
    Oct
MCFE McAfee
$21.78 /

+0.58 (+2.74%)

MCFE McAfee
$21.78 /

+0.58 (+2.74%)

Hot Stocks
Amerant Bancorp names Kristy Amaro as Chief Diversity & Inclusion Officer » 18:04
09/16/21
09/16
18:04
09/16/21
18:04
AMTB

Amerant Bancorp

$24.59 /

-0.73 (-2.88%)

Amerant Bancorp announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMTB Amerant Bancorp
$24.59 /

-0.73 (-2.88%)

AMTB Amerant Bancorp
$24.59 /

-0.73 (-2.88%)

08/30/21
Fly Intel: Top five analyst upgrades
08/30/21 Piper Sandler
Amerant Bancorp upgraded to Overweight from Neutral at Piper Sandler
06/02/21 Stephens
Amerant Bancorp initiated with an Equal Weight at Stephens
05/17/21 Truist
Amerant Bancorp price target raised to $25 from $18 at Truist
AMTB Amerant Bancorp
$24.59 /

-0.73 (-2.88%)

Hot Stocks
McAfee CEO Leav sells nearly 130,000 class A shares » 18:04
09/16/21
09/16
18:04
09/16/21
18:04
MCFE

McAfee

$21.78 /

+0.58 (+2.74%)

In a regulatory filing,…

In a regulatory filing, McAfee president and CEO Peter Leav disclosed the sale of 129,591 class A common shares of the company on September 14 at a price of $21.7125 per share.

ShowHide Related Items >><<
MCFE McAfee
$21.78 /

+0.58 (+2.74%)

MCFE McAfee
$21.78 /

+0.58 (+2.74%)

09/13/21 Morgan Stanley
McAfee pullback a 'strong buying opportunity,' says Morgan Stanley
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 UBS
McAfee resumed to Neutral from Buy at UBS
06/17/21 Mizuho
McAfee price target raised to $30 from $28 at Mizuho
MCFE McAfee
$21.78 /

+0.58 (+2.74%)

  • 10
    Sep
  • 22
    Oct
MCFE McAfee
$21.78 /

+0.58 (+2.74%)

MCFE McAfee
$21.78 /

+0.58 (+2.74%)

Periodicals
Invesco in talks over tie-up with State Street's asset management unit, WSJ says » 18:00
09/16/21
09/16
18:00
09/16/21
18:00
STT

State Street

$87.03 /

-0.9 (-1.02%)

, IVZ

Invesco

$24.88 /

-0.67 (-2.62%)

Invesco (IVZ) is in…

Invesco (IVZ) is in discussions to combine with State Street's (STT) asset management unit, the Wall Street Journal's Justin Baer and Cara Lombardo report, citing people familiar with the matter. An agreement is not imminent, and talks may not result in a deal, the authors note. Reference Link

ShowHide Related Items >><<
STT State Street
$87.03 /

-0.9 (-1.02%)

IVZ Invesco
$24.88 /

-0.67 (-2.62%)

STT State Street
$87.03 /

-0.9 (-1.02%)

09/09/21 JPMorgan
JPMorgan expects 'sizable equity issue' from State Street after deal
09/08/21 Jefferies
State Street pullback on BBH deal a buying opportunity, says Jefferies
09/08/21 Morgan Stanley
Brown Brothers Harriman to make State Street more efficient, says Morgan Stanley
07/19/21 Deutsche Bank
State Street price target raised to $105 from $104 at Deutsche Bank
IVZ Invesco
$24.88 /

-0.67 (-2.62%)

07/12/21 Deutsche Bank
Invesco price target raised to $35 from $33 at Deutsche Bank
07/12/21 Citi
Invesco upgraded to Buy from Neutral at Citi
04/09/21 Deutsche Bank
Invesco price target raised to $31 from $28 at Deutsche Bank
01/28/21
Fly Intel: Top five analyst upgrades
STT State Street
$87.03 /

-0.9 (-1.02%)

IVZ Invesco
$24.88 /

-0.67 (-2.62%)

  • 10
    Sep
STT State Street
$87.03 /

-0.9 (-1.02%)

STT State Street
$87.03 /

-0.9 (-1.02%)

STT State Street
$87.03 /

-0.9 (-1.02%)

IVZ Invesco
$24.88 /

-0.67 (-2.62%)

Conference/Events
FDA Pediatric Advisory Committee to hold a meeting » 17:40
09/16/21
09/16
17:40
09/16/21
17:40

The Committee discusses…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Yum China to hold virtual investor day » 17:38
09/16/21
09/16
17:38
09/16/21
17:38
YUMC

Yum China

$55.68 /

-1.915 (-3.33%)

Virtual Investor Day to…

Virtual Investor Day to be held on September 22 at 8 pm. Webcast Link

ShowHide Related Items >><<
YUMC Yum China
$55.68 /

-1.915 (-3.33%)

YUMC Yum China
$55.68 /

-1.915 (-3.33%)

09/15/21 Macquarie
Macquarie downgrades Yum China to sell on 'bumpy' sales recovery
09/15/21 Macquarie
Yum China downgraded to Underperform from Neutral at Macquarie
07/07/21 Goldman Sachs
Yum China price target raised to $77 from $74 at Goldman Sachs
04/29/21 RBC Capital
Yum China price target raised to $123 from $112 at RBC Capital
YUMC Yum China
$55.68 /

-1.915 (-3.33%)

YUMC Yum China
$55.68 /

-1.915 (-3.33%)

YUMC Yum China
$55.68 /

-1.915 (-3.33%)

Hot Stocks
Ballard Power launches FCmove product for buses and trucks » 17:31
09/16/21
09/16
17:31
09/16/21
17:31
BLDP

Ballard Power

$15.14 /

-0.035 (-0.23%)

The company states:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BLDP Ballard Power
$15.14 /

-0.035 (-0.23%)

BLDP Ballard Power
$15.14 /

-0.035 (-0.23%)

09/13/21 Eight Capital
Ballard Power initiated with a Neutral at Eight Capital
08/31/21 Wolfe Research
Ballard Power initiated with an Underperform at Wolfe Research
05/05/21 BMO Capital
Ballard Power price target lowered to $23 from $35 at BMO Capital
05/05/21 B. Riley
Ballard Power price target lowered to $26 from $30 at B. Riley
BLDP Ballard Power
$15.14 /

-0.035 (-0.23%)

  • 10
    Mar
  • 10
    Feb
  • 24
    Nov
BLDP Ballard Power
$15.14 /

-0.035 (-0.23%)

BLDP Ballard Power
$15.14 /

-0.035 (-0.23%)

Conference/Events
Sprout Social to hold virtual investor day » 17:31
09/16/21
09/16
17:31
09/16/21
17:31
SPT

Sprout Social

$135.29 /

+1.77 (+1.33%)

Virtual Investor Day to…

Virtual Investor Day to be held on September 22 at 10 am. Webcast Link

ShowHide Related Items >><<
SPT Sprout Social
$135.29 /

+1.77 (+1.33%)

09/07/21 Stifel
Sprout Social price target raised to $135 from $105 at Stifel
08/04/21 Canaccord
Sprout Social price target raised to $100 from $77 at Canaccord
07/23/21 Barclays
Sprout Social price target raised to $106 from $77 at Barclays
07/16/21 Stifel
Sprout Social price target raised to $95 from $85 at Stifel
SPT Sprout Social
$135.29 /

+1.77 (+1.33%)

SPT Sprout Social
$135.29 /

+1.77 (+1.33%)

Hot Stocks
Methanex approves 5% share repurchase program » 17:29
09/16/21
09/16
17:29
09/16/21
17:29
MEOH

Methanex

$41.63 /

+0.64 (+1.56%)

Methanex has approved a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MEOH Methanex
$41.63 /

+0.64 (+1.56%)

MEOH Methanex
$41.63 /

+0.64 (+1.56%)

09/13/21 Piper Sandler
Methanex initiated with a Neutral at Piper Sandler
09/07/21 Barclays
Methanex upgraded to Overweight from Equal Weight at Barclays
09/01/21 RBC Capital
Methanex to generate strong cash flows in 2021-22, says RBC Capital
07/19/21 TD Securities
Methanex price target raised to $54 from $51 at TD Securities
MEOH Methanex
$41.63 /

+0.64 (+1.56%)

Hot Stocks
ShotSpotter CFO Stewart purchases 5K shares of company stock » 17:27
09/16/21
09/16
17:27
09/16/21
17:27
SSTI

ShotSpotter

$34.83 /

-0.19 (-0.54%)

ShotSpotter CFO Alan…

ShotSpotter CFO Alan Stewart disclosed in a filing that he had purchased 5,000 shares of company stock at $34.74 per share between September 14 and September 15, for a total transaction value of $173,716.

ShowHide Related Items >><<
SSTI ShotSpotter
$34.83 /

-0.19 (-0.54%)

SSTI ShotSpotter
$34.83 /

-0.19 (-0.54%)

08/11/21 Roth Capital
ShotSpotter price target raised to $60 from $53 at Roth Capital
06/21/21 Craig-Hallum
ShotSpotter price target raised to $49 from $45 at Craig-Hallum
05/12/21 Craig-Hallum
ShotSpotter upgraded to Buy from Hold at Craig-Hallum
03/31/21 Craig-Hallum
ShotSpotter price target lowered to $40 from $45 at Craig-Hallum
SSTI ShotSpotter
$34.83 /

-0.19 (-0.54%)

SSTI ShotSpotter
$34.83 /

-0.19 (-0.54%)

SSTI ShotSpotter
$34.83 /

-0.19 (-0.54%)

Hot Stocks
Ranger Energy to acquire Basic Energy Services assets from Chapter 11 bankruptcy » 17:26
09/16/21
09/16
17:26
09/16/21
17:26
RNGR

Ranger Energy

$8.48 /

-0.64 (-7.02%)

Ranger Energy Services…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RNGR Ranger Energy
$8.48 /

-0.64 (-7.02%)

RNGR Ranger Energy
$8.48 /

-0.64 (-7.02%)

08/20/21 Piper Sandler
Ranger Energy price target raised to $8 from $5 at Piper Sandler
07/19/21 Barclays
Ranger Energy upgraded to Overweight from Equal Weight at Barclays
03/04/21 B. Riley
Ranger Energy price target raised to $7.50 from $6 at B. Riley Securities
01/04/21 Evercore ISI
Ranger Energy upgraded to Outperform from In Line at Evercore ISI
RNGR Ranger Energy
$8.48 /

-0.64 (-7.02%)

Conference/Events
Wheaton Precious Metals to hold virtual investor day » 17:25
09/16/21
09/16
17:25
09/16/21
17:25
WPM

Wheaton Precious Metals

$41.64 /

-2.58 (-5.83%)

Virtual Investor Day to…

Virtual Investor Day to be held on September 22 at 8:30 am. Webcast Link

ShowHide Related Items >><<
WPM Wheaton Precious Metals
$41.64 /

-2.58 (-5.83%)

WPM Wheaton Precious Metals
$41.64 /

-2.58 (-5.83%)

09/10/21 National Bank
Wheaton Precious Metals price target lowered to C$72 from C$75 at National Bank
07/08/21 Berenberg
Wheaton Precious Metals price target raised to 3,800 GBp at Berenberg
05/20/21 National Bank
Wheaton Precious Metals price target raised to C$75 at National Bank
04/27/21 JPMorgan
Wheaton Precious Metals price target lowered to $53 from $58 at JPMorgan
WPM Wheaton Precious Metals
$41.64 /

-2.58 (-5.83%)

Hot Stocks
VeriSign CEO sells 8K shares of common stock » 17:23
09/16/21
09/16
17:23
09/16/21
17:23
VRSN

VeriSign

$224.87 /

+0.65 (+0.29%)

In a regulatory filing,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VRSN VeriSign
$224.87 /

+0.65 (+0.29%)

VRSN VeriSign
$224.87 /

+0.65 (+0.29%)

04/23/21 Citi
VeriSign price target raised to $245 from $235 at Citi
12/09/20
Fly Intel: Top five analyst upgrades
12/09/20 JPMorgan
VeriSign upgraded to Overweight from Neutral at JPMorgan
VRSN VeriSign
$224.87 /

+0.65 (+0.29%)

VRSN VeriSign
$224.87 /

+0.65 (+0.29%)

Conference/Events
Boston Scientific to hold virtual investor day » 17:22
09/16/21
09/16
17:22
09/16/21
17:22
BSX

Boston Scientific

$44.91 /

-0.1 (-0.22%)

Virtual Investor Day to…

Virtual Investor Day to be held on September 22 at 8:30 am. Webcast Link

ShowHide Related Items >><<
BSX Boston Scientific
$44.91 /

-0.1 (-0.22%)

BSX Boston Scientific
$44.91 /

-0.1 (-0.22%)

09/14/21 Piper Sandler
CMS full repeal proposal of MCIT negative for med tech, says Piper Sandler
08/31/21 BTIG
Abbott price target raised to $136 from $126 at BTIG
08/31/21 Barclays
Abbott's Amulet could become 'needle mover,' says Barclays
08/30/21 Piper Sandler
Boston Scientific's Watchman still well positioned, says Piper Sandler
BSX Boston Scientific
$44.91 /

-0.1 (-0.22%)

BSX Boston Scientific
$44.91 /

-0.1 (-0.22%)

BSX Boston Scientific
$44.91 /

-0.1 (-0.22%)

BSX Boston Scientific
$44.91 /

-0.1 (-0.22%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.